A Novel Platform
An entirely new class of ultra-small, precision-engineered tumor targeted therapeutics that represent a breakthrough in treating patients with cancer.
From the October 29, 2014 cover of Science Translational Medicine. Illustration: V. Altounian, C. Bickel/ Science Translational Medicine. Reprinted with permission from AAAS.
An entirely new class of ultra-small, precision-engineered tumor targeted therapeutics that represent a breakthrough in treating patients with cancer.
Early human clinical data has been published and pilot clinical trials are ongoing.
Elucida Oncology is focused primarily on developing precision targeted C’Dot Drug Conjugate therapeutics or CDCs to treat patients with complex cancers.
In addition to developing therapeutics, we have advanced several clinical and preclinical programs in diagnostic imaging and surgical applications that we are seeking to work with experienced industry partners for further clinical development.
Learn More